Related Experiment Video
Updated: Mar 29, 2026
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Clinical Profiles and Lung Function Trajectories of Patients With Idiopathic Inflammatory Myopathy Associated
Rachele Vallara1, Helena Andersson2, Ilaria Bassi1
1Department of Medical and Surgical Sciences DIMEC, University of Bologna, Bologna - Forlì, Italy; Respiratory and Critical Care Unit, IRCCS S. Orsola-Malpighi Hospital, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Background:
Idiopathic inflammatory myopathies (IIMs) are frequently complicated by interstitial lung disease (ILD). Although clinical heterogeneity is recognized, comparisons between patients with idiopathic inflammatory myopathy associated interstial lung disease (IIM-ILD) managed in pulmonology vs rheumatology centers remain limited.
Research Question:
Do differences in clinical features, treatment strategies, lung function trajectories, and transplant-free survival among patients with IIM-ILD followed at pulmonology or rheumatology centers exist?
Study Design And Methods:
We conducted a multicenter, observational, cohort study including 75 patients with IIM-ILD diagnosed between 2014 and 2024: 25 from 2 Italian pulmonology centers and 50 from a rheumatology center in Norway. All met IIM classification criteria, had ILD confirmed by high-resolution CT scan, and had serial pulmonary function tests. Associations of baseline features, imaging patterns, and treatments with referral center were assessed using logistic regression. Lung function trajectories were assessed with linear mixed-effects models and transplant-free survival with Cox regression.
Results:
Patients with IIM-ILD from pulmonology centers were more often male, had more fibrotic ILD (OR, 5.61; 95% CI, 1.88-16.73; P = .002), had lower baseline diffusing capacity of the lungs for carbon monoxide (OR, 0.96; 95% CI, 0.93-0.99; P = .048), had less cutaneous (OR, 0.11; 95% CI, 0.03-0.40; P = .001) and musculoskeletal involvement, and used less rituximab (OR, 0.06; 95% CI, 0.01-0.23; P < .001) than patients from rheumatology centers. Despite baseline differences, both cohorts showed significant and comparable improvement in FVC and diffusing capacity of the lungs for carbon monoxide % predicted over a mean of 2.5 years. Transplant-free survival did not differ significantly between specialty centers. Factors associated with worse transplant-free survival included anti-MDA5 positivity (hazard ratio, 10.24; 95% CI, 1.70-61.66; P = .011), elevated C-reactive protein, and extensive lung fibrosis.
Interpretation:
Our results show that although baseline presentation and treatment characteristics of patients with IIM-ILD differed between rheumatology and pulmonology cohorts, transplant-free survival was comparable. Including patients from both pulmonology and rheumatology in future clinical trials may enhance representativeness without compromising data consistency.
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:25Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...